New York, New York–(Newsfile Corp. – April 29, 2022) – The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased AbbVie Inc. (“AbbVie”) (NYSE: ABBV) between April 30, 2021 and August 31, 2021.

If you suffered a loss, contact us at the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/abbvie-inc-loss-submission-form-2?prid=26569&wire=5.

Allegations against ABBV include that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) safety concerns about Pfizer Inc.’s drug Xeljanz extended to Abbvie’s drug Rinvoq and to other Janus kinase enzyme inhibitor drugs; (2) as a result, it was likely that the U.S. Food and Drug Administration would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis.

If you suffered a loss in AbbVie you have until June 6, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/122214